目的 探讨儿童髓鞘少突胶质细胞糖蛋白（MOG）抗体相关疾病（MOGAD）患儿的临床特点及治疗转归。方法 回顾性分析28例MOGAD患儿（38例次脱髓鞘发作）的临床资料。结果 28例MOGAD患儿的疾病谱中，视神经炎占比最高（12例，43%），其次为急性播散性脑脊髓炎（9例，32%）。28例患儿（38例次脱髓鞘发作）急性期头颅MRI显示病变者共29例次（76%），大部分表现为广泛性或孤立性皮质下白质病灶。共记录24例次急性发作期脊髓MRI结果，其中脊髓病变者11例次（46%）。18例次视神经炎急性期MRI显示均伴视神经病变。20例（71%）患儿脑脊液白细胞升高，细胞分类以淋巴细胞为主，蛋白升高者3例。28例患儿血清MOG抗体滴度1：10~1：320。28例患儿均给予了糖皮质激素治疗，18例同时予以免疫球蛋白治疗。随访中26例（93%）治疗后症状基本缓解，仅2例遗留视觉能区的神经系统后遗症。结论 MOGAD儿童的临床表现呈多样性；免疫治疗有效，大部分预后良好。
Abstract
Objective To study the clinical features and treatment outcome of children with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorders (MOGAD). Methods A retrospective analysis was performed for the clinical data of 28 children with MOGAD (with 38 demyelinating episodes). Results Among the disease spectrums of 28 children with MOGAD, optic neuritis was the most common (12 cases, 43%), followed by acute disseminated encephalomyelitis (9 cases, 32%). Among the 38 demyelinating episodes in the 28 children, there were 29 cases (76%) of lesions in the acute stage on head magnetic resonance imaging (MRI), and most of these lesions were extensive or isolated subcortical white matter lesions. A total of 24 cases of spinal MRI results in the acute stage were recorded, among which there were 11 cases (46%) of spinal lesions. MRI abnormalities of the optic nerve were found in 18 cases of optic neuritis in the acute stage. Of the 28 children, 20 (71%) had an increase in white blood cell count in cerebrospinal fluid, with lymphocytes as the most common type of cells, and 3 children had an increase in protein. The titer of serum MOG antibody was 1:10-1:320 in the 28 children. All 28 children were administered with glucocorticoids, along with immunoglobulin in 18 children. The symptoms of 26 children (93%) were alleviated during follow-up, and only 2 children had neurological sequela of the optic function. Conclusions The clinical manifestations are diverse in children with MOGAD. Immunotherapy is effective and most children have a good prognosis.
关键词
髓鞘少突胶质细胞糖蛋白抗体相关疾病 /
脱髓鞘发作 /
儿童
Key words
Myelin oligodendrocyte glycoprotein antibody-associated disorder /
Demyelinating episode /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease[J]. Nat Rev Neurol, 2019, 15(2):89-102.
[2] Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody[J]. JAMA Neurol, 2019, 76(3):301-309.
[3] Jurynczyk M, Geraldes R, Probert F, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis[J]. Brain, 2017, 140(3):617-627.
[4] Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis:international recommendations on diagnosis and antibody testing[J]. J Neuroinflammation, 2018, 15(1):134.
[5] Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody:the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination[J]. Autoimmun Rev, 2016, 15(4):307-324.
[6] Nagabushana D, Shah R, Pendharkar H, et al. MOG antibody seropositive aseptic meningitis:a new clinical phenotype[J]. J Neuroimmunol, 2019, 333:476960.
[7] Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease:a UK study[J]. Brain, 2017, 140(12):3128-3138.
[8] Cobo-Calvo A, Vukusic S, Marignier R. Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults[J]. Curr Opin Neurol, 2019, 32(3):459-466.
[9] Hennes EM, Baumann M, Lechner C, et al. MOG spectrum disorders and role of MOG-antibodies in clinical practice[J]. Neuropediatrics, 2018, 49(1):3-11.
[10] Ogawa R, Nakashima I, Takahashi T, et al. MOG antibodypositive, benign, unilateral, cerebral cortical encephalitis with epilepsy[J]. Neurol Neuroimmunol Neuroinflamm, 2017, 4(2):e322.
[11] Ikeda T, Yamada K, Ogawa R, et al. The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies:a case report[J]. J Neurol Sci, 2018, 392:113-115.
[12] 周季, 张尧, 季涛云, 等. 儿童视神经脊髓炎谱系疾病临床分析[J]. 中华儿科杂志, 2019, 57(2):118-124.
[13] Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome[J]. Neurology, 2017, 89(9):900-908.
[14] Kim SM, Woodhall MR, Kim JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS[J]. Neurol Neuroimmunol Neuroinflamm, 2015, 2(6):e163.
[15] Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults:the MOGADOR study[J]. Neurology, 2018, 90(21):e1858-e1869.
[16] Hyun JW, Woodhall MR, Kim SH, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases[J]. J Neurol Neurosurg Psychiatry, 2017, 88(10):811-817.
[17] López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOGIgG-associated disorders[J]. JAMA Neurol, 2018, 75(11):1355-1363.
[18] Spadaro M, Gerdes LA, Mayer MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis[J]. Ann Clin Transl Neurol, 2015, 2(3):295-301.
[19] Zhou Y, Jia X, Yang H, et al. Myelin oligodendrocyte glycoprotein antibody-associated demyelination:comparison between onset phenotypes[J]. Eur J Neurol, 2019, 26(1):175-183.
[20] Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders:a multicenter study of 50 patients. Part 2:Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome[J]. J Neuroinflammation, 2016, 13(1):280.
[21] Polat İ, Yiş U, Karaoğlu P, et al. Myelin oligodendrocyte glycoprotein antibody persistency in a steroid-dependent ADEM case[J]. Pediatrics, 2016, 137(5). pii:e20151958.
[22] Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease[J]. JAMA Neurol, 2018, 75(4):478-487.
PDF(1941 KB)
